Other

Early Aggressive vs Traditional Therapy for Multiple Sclerosis (TREAT-MS Trial)

Kansas City, KS

N/A

Waitlist Available

Led By Ellen M. Mowry, MD, MCR

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged 18-60 years

Meets 2017 McDonald criteria for relapsing-remitting MS [patients with clinically isolated syndrome (CIS) are not eligible]

Timeline

Screening 1 day

Treatment 84 months

Follow Up from 6 months after starting 1st therapy up to 99 months after randomization

Awards & highlights

No Placebo-Only Group

Summary

This trial will help researchers understand if an early aggressive therapy approach is better than a traditional first-line therapy approach for preventing long-term disability in MS patients.

See full description

Who is the study for?

This trial is for adults aged 18-60 with relapsing-remitting Multiple Sclerosis who meet specific criteria and have not had chemotherapy in the past year. They must test negative or low positive for JC virus, and negative for Hepatitis B/C, tuberculosis, and HIV.Check my eligibility

What is being tested?

The TREAT-MS trial compares two approaches: 'early aggressive' therapy versus traditional first-line treatments to see which better prevents long-term disability in MS patients at different risk levels of disability accumulation.See study design

What are the potential side effects?

Early aggressive therapy may increase the risk of infections and other complications due to its higher efficacy compared to traditional therapies. The exact side effects will depend on the specific treatments used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 60 years old.

show original

Select...

You meet 2017 McDonald criteria for relapsing-remitting MS.

show original

Select...

I don't have JC virus, hepatitis B or C, or tuberculosis.

show original

Select...

You are HIV negative.

show original

Select...

I haven't had chemotherapy in the last year and if I had cancer before, my doctor has noted why stronger treatment is needed.

show original

Timeline

Screening ~ 1 day1 visit

Treatment ~ 84 months15 visits

Follow Up ~ from 6 months after starting 1st therapy up to 99 months after randomization

Screening ~ 1 day

Treatment ~ 84 months

Follow Up ~from 6 months after starting 1st therapy up to 99 months after randomization

This trial's timeline: 1 day for screening, 84 months for treatment, and from 6 months after starting 1st therapy up to 99 months after randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Overall Burden of MS

Time to sustained disability progression

Secondary study objectives

Adverse event resulting in a decision to change disease-modifying therapy

Cognition using Symbol Digit Modality Test (SDMT)

Employment status

+23 more

Other study objectives

Brain Magnetic Resonance Imaging (MRI) evidence of neurodegeneration

Brain

Pharmaceutical Preparations

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: Early Aggressive TherapyActive Control1 Intervention

Early Aggressive Therapy choices and maximum allowable doses: * Natalizumab/natalizumab-sztn (Tysabri/Tyruko), 300 mg IV q 4 wks * Alemtuzumab (Lemtrada), 12 mg IV daily (QD) for 5 days; 1 yr later: 12 mg IV QD for 3 days * Ocrelizumab (Ocrevus), 300 mg IV every 2 wks (for 2 doses) at initiation; 600 mg IV q 6 mths * Rituximab/rituximab biosimilars (Rituxan/Riabni/Truxima/Ruxience), 1000 mg IV every 2 wks (for 2 doses); may repeat q 16-24 wks * Cladribine (Mavenclad), 3.5 mg per kg body wt orally divided into 2 yrly tmt courses (1.75 mg per kg body wt each yr); yrly tmt course divided into 2 tmt cycles; administer cycle dose as 1-2 tablets QD over 4-5 days * Ofatumumab (Kesimpta), 20 mg SC wkly for wks 0, 1 and 2; 20 mg subcutaneously (SC) mthly starting at wk 4 * Ublituximab-xiiy (Briumvi), 150 mg IV (1st dose); 450 mg IV 2 wks after first dose; 450 mg IV q 24 wks * Ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo), 920 mg ocrelizumab and 23,000 U hyaluronidase SC q 6 months

Group II: Traditional TherapyActive Control1 Intervention

Traditional Therapy choices and maximum allowable doses: * Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg SC daily, or 40 mg SC 3 times a wk * Intramuscular (IM) interferon (Avonex), 30 mcg IM weekly * SC interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC 3 times a wk (Rebif) * Pegylated interferon (Plegridy), 125 mcg SC every 14 days * Teriflunomide (Aubagio), 14 mg PO QD * Dimethyl fumarate (Tecfidera and generics), 240 mg PO twice a day (BID) * Diroximel fumarate (Vumerity), 462 mg PO BID * Monomethyl fumarate (Bafiertam), 190 mg PO BID * Fingolimod (Gilenya and generics), 0.5 mg PO QD * Siponimod (Mayzent), 1 mg PO QD or 2 mg PO QD * Ozanimod (Zeposia), 0.92 mg PO QD * Ponesimod (Ponvory), 20 mg PO QD * Fingolimod ODT (Tascenso), 0.25 mg PO QD if \<=40 kg; 0.5 mg PO QD if \> 40 kg

0 / 5Eligibility criteria met